Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
8 "Wei Xu"
Filter
Filter
Article category
Keywords
More +
Publication year
Authors
More +
Funded articles
More +
Original Articles
Genitourinary cancer
Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
Xiaochen Fei, Xinxing Du, Yiming Gong, Jiazhou Liu, Liancheng Fan, Jiayi Wang, Yanqing Wang, Yinjie Zhu, Jiahua Pan, Baijun Dong, Wei Xue
Cancer Res Treat. 2023;55(3):969-977.   Published online March 2, 2023
DOI: https://doi.org/10.4143/crt.2022.1557
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting disease recurrence.
Materials and Methods
This real-world observational study evaluated 161 cases of nmPCa undergoing next-generation sequencing at our institution. A total of 139 ctDNA samples and 31 biopsied tumor tissue underwent genomic profiling. The study endpoint was BCR after radical prostatectomy. Relationships between the ctDNA status and the biochemical progression-free survival (bPFS) were analyzed by log-rank test and multivariate Cox regression.
Results
Of 161 enrolled patients, 19 (11.8%) harbored deleterious alterations in NCOR2, followed by BRCA2 (3.7%), ATR (2.5%), and CDK12 (2.5%). Of available pre-operative blood samples (n=139), ctDNA was detectable in 91 (65.5%). Until last follow-up, 56 of 68 patients (85.3%) with detectable ctDNA had achieved BCR, whereas only eight of 39 patients (20.5%) with undetectable ctDNA had achieved BCR. Patients who had undetectable ctDNA experienced significantly longer bPFS compared with those who had detectable ctDNA (not available vs. 8.2 months; hazard ratio, 0.14; p < 0.01). Pre-operative ctDNA status was a significant prognostic factor of disease recurrence.
Conclusion
Pre-operative ctDNA detection could identify patients at high risk of recurrence and has the potential to inform immediate postoperative interventions, but these approaches remain to be validated in prospective studies. ctDNA studies can provide insights into accurate monitoring and precise treatment rather than simply following routine clinical care.

Citations

Citations to this article as recorded by  
  • Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy
    Marcel Figueras, Lourdes Mengual, Mercedes Ingelmo-Torres, Fiorella L. Roldán, Bernat Padullés, Héctor Alfambra, Sandra Herranz, Pilar Paredes, Gary Amseian, Joel Mases, Maria J. Ribal, Laura Izquierdo, Antonio Alcaraz
    Diagnostics.2024; 14(20): 2293.     CrossRef
  • Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients
    Tatiana M. Zavarykina, Polina K. Lomskova, Irina V. Pronina, Svetlana V. Khokhlova, Marina B. Stenina, Gennady T. Sukhikh
    International Journal of Molecular Sciences.2023; 24(23): 17073.     CrossRef
  • 3,443 View
  • 185 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Lung and Thoracic cancer
MLL4 Regulates the Progression of Non–Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
Yang Yang, Rongfang Qiu, Qiaoyou Weng, Ziwei Xu, Jingjing Song, Siyu Zhao, Miaomiao Meng, Dengke Zhang, Chunli Kong, Hailin Wang, Min Xu, Zhongwei Zhao, Jiansong Ji
Cancer Res Treat. 2023;55(3):778-803.   Published online January 26, 2023
DOI: https://doi.org/10.4143/crt.2022.1042
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mixed-lineage leukemia protein 4 (MLL4/KMT2D) is a histone methyltransferase, and its mutation has been reported to be associated with a poor prognosis in many cancers, including lung cancer. We investigated the function of MLL4 in lung carcinogenesis.
Materials and Methods
RNA sequencing (RNA-seq) in A549 cells transfected with control siRNA or MLL4 siRNA was performed. Also, we used EdU incorporation assay, colony formation assays, growth curve analysis, transwell invasion assays, immunohistochemical staining, and in vivo bioluminescence assay to investigate the function of MLL4 in lung carcinogenesis.
Results
We found that MLL4 expression was downregulated in non–small cell lung cancer (NSCLC) tissues compared to adjacent normal tissues and tended to decrease with disease stage progression. We analyzed the transcriptomes in control and MLL4- deficient cells using high-throughput RNA deep sequencing (RNA-seq) and identified a cohort of target genes, such as SOX2, ATF1, FOXP4, PIK3IP1, SIRT4, TENT5B, and LFNG, some of which are related to proliferation and metastasis. Our results showed that low expression of MLL4 promotes NSCLC cell proliferation and metastasis and is required for the maintenance of NSCLC stem cell properties.
Conclusion
Our findings identify an important role of MLL4 in lung carcinogenesis through transcriptional regulation of PIK3IP1, affecting the PI3K/AKT/SOX2 axis, and suggest that MLL4 could be a potential prognostic indicator and target for NSCLC therapy.

Citations

Citations to this article as recorded by  
  • Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer
    Linxiang Zhang, Xueying Zhang, Yan Shi, Yuhan Ni, Jiaojiao Fei, Zhixin Jin, Wenjuan Li, Xiaojing Wang, Nan Wu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The multifaceted role of SOX2 in breast and lung cancer dynamics
    Kiavash Hushmandi, Seyed Hassan Saadat, Seyedalireza Mirilavasani, Salman Daneshi, Amir Reza Aref, Noushin Nabavi, Rasoul Raesi, Afshin Taheriazam, Mehrdad Hashemi
    Pathology - Research and Practice.2024; 260: 155386.     CrossRef
  • PIK3IP1: structure, aberration, function, and regulation in diseases
    Yingjie Jia, Pengxing He, Xubin Ma, Kaili Lv, Ying Liu, Yichao Xu
    European Journal of Pharmacology.2024; 977: 176753.     CrossRef
  • UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway
    Li He, Heng Chen, Bin Ruan, Li He, Ming Luo, Yulun Fu, Rui Zou
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Role of histone methyltransferase KMT2D in BMSC osteogenesis via AKT signaling
    Zhichun Zhang, Yanyan Guo, Xuejun Gao, Xiaoyan Wang, Chanyuan Jin
    Regenerative Therapy.2024; 26: 775.     CrossRef
  • Landscape of targeted therapies for lung squamous cell carcinoma
    Qiuxuan Chen, Xiaoshuo Zheng, Weiting Cheng, Jian Li
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • 4,440 View
  • 275 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
EBV-miR-BHRF1-1 Targets p53 Gene: Potential Role in Epstein-Barr Virus Associated Chronic Lymphocytic Leukemia
Dan-Min Xu, Yi-Lin Kong, Li Wang, Hua-Yuan Zhu, Jia-Zhu Wu, Yi Xia, Yue Li, Shu-Chao Qin, Lei Fan, Jian-Yong Li, Jin-Hua Liang, Wei Xu
Cancer Res Treat. 2020;52(2):492-504.   Published online October 29, 2019
DOI: https://doi.org/10.4143/crt.2019.457
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the prognostic impact of Epstein-Barr virus (EBV)–microRNA (miRNA, miR)-BHRF1-1 with chronic lymphocytic leukemia (CLL) as well as role of EBV-miR-BHRF1-1 in p53 gene.
Materials and Methods
Quantitative reverse transcription–polymerase chain reaction and western blotting were used to quantify EBV-miR-BHRF1-1 and p53 expression in cultured CLL.
Results
p53 aberration was associated with the higher expression level of EBV-miR-BHRF1-1 (p < 0.001) which was also an independent prognostic marker for overall survival (p=0.028; hazard ratio, 5.335; 95% confidence interval, 1.193 to 23.846) in 97 newly-diagnosed CLL patients after adjusted with International Prognostic Index for patients with CLL. We identified EBV-miR-BHRF1-1 as a viral miRNA regulator of p53. EBV-miR-BHRF1-1 repressed luciferase reporter activity by specific interaction with the seed region within the p53 3′- untranslated region. Discordance of p53 messenger RNA and protein expression was associated with high EBV-miR-BHRF1-1 levels in CLL patients and cell lines. EBV-miR-BHRF1- 1 inhibition upregulated p53 protein expression, induced cell cycle arrest and apoptosis and decreased cell proliferation in cell lines. EBV-miR-BHRF1-1 mimics downregulated p53 protein expression, decreased cell cycle arrest and apoptosis, and induced cell proliferation in cell lines.
Conclusion
This study supported the role of EBV-miR-BHRF1-1 in p53 regulation in vitro. Our results support the potential of EBV-miR-BHRF1-1 as a therapeutic target in EBV-associated CLL with p53 gene aberration.

Citations

Citations to this article as recorded by  
  • Longitudinal analysis of the impact of rituximab on circulating EBV miRNAs in three paediatric kidney transplant recipients
    Jaythoon Hassan, Gabriel Gonzalez, Maria Stack, Niamh Dolan, Clodagh Sweeney, Cillian De Gascun, Jeff Connell, Atif Awan, Michael Riordan
    Journal of Clinical Virology Plus.2024; 4(1): 100171.     CrossRef
  • Epstein-Barr virus deubiquitinating enzyme BPLF1 is involved in EBV carcinogenesis by affecting cellular genomic stability
    Hantao Wu, Bo-Wei Han, Tiancai Liu, Min Zhang, Yingsong Wu, Jing Nie
    Neoplasia.2024; 55: 101012.     CrossRef
  • The Emerging Role of Ferroptosis in EBV-Associated Cancer: Implications for Cancer Therapy
    Shan He, Cheng Luo, Feng Shi, Jianhua Zhou, Li Shang
    Biology.2024; 13(7): 543.     CrossRef
  • A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection
    Seyedeh Zahra Bahojb Mahdavi, Asiyeh Jebelli, Parisa Shiri Aghbash, Behzad Baradaran, Mohammad Amini, Fatemeh Oroojalian, Nasser Pouladi, Hossein Bannazadeh Baghi, Miguel de la Guardia, Amir Ali Mokhtarzadeh
    Medicinal Research Reviews.2024;[Epub]     CrossRef
  • From virus to cancer: Epstein–Barr virus miRNA connection in Burkitt's lymphoma
    Shahram Jalilian, Mohammad-Navid Bastani
    Infectious Agents and Cancer.2024;[Epub]     CrossRef
  • MicroRNAs: Small but Key Players in Viral Infections and Immune Responses to Viral Pathogens
    Anais N. Bauer, Niska Majumdar, Frank Williams, Smit Rajput, Lok R. Pokhrel, Paul P. Cook, Shaw M. Akula
    Biology.2023; 12(10): 1334.     CrossRef
  • Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology
    Rodney Hull, Rahaba Marima, Mohammed Alaouna, Demetra Demetriou, Rui Manuel Reis, Thulo Molefi, Zodwa Dlamini
    Microorganisms.2022; 10(7): 1448.     CrossRef
  • MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia
    Katerina Katsaraki, Paraskevi Karousi, Pinelopi I. Artemaki, Andreas Scorilas, Vasiliki Pappa, Christos K. Kontos, Sotirios G. Papageorgiou
    Cancers.2021; 13(4): 593.     CrossRef
  • Metabolic Control by DNA Tumor Virus-Encoded Proteins
    Martin A. Prusinkiewicz, Joe S. Mymryk
    Pathogens.2021; 10(5): 560.     CrossRef
  • Non-Coding RNAs: Strategy for Viruses’ Offensive
    Alessia Gallo, Matteo Bulati, Vitale Miceli, Nicola Amodio, Pier Giulio Conaldi
    Non-Coding RNA.2020; 6(3): 38.     CrossRef
  • EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives
    Keran Sun, Keqi Jia, Huifang Lv, Sai-Qi Wang, Yan Wu, Huijun Lei, Xiaobing Chen
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • 7,121 View
  • 208 Download
  • 14 Web of Science
  • 11 Crossref
Close layer
Diabetes Mellitus Is Associated with Inferior Prognosis in Patients with Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis
Rui Gao, Tian-Shuo Man, Jin-Hua Liang, Li Wang, Hua-Yuan Zhu, Wei Wu, Lei Fan, Jian-Yong Li, Tao Yang, Wei Xu
Cancer Res Treat. 2020;52(1):189-206.   Published online July 1, 2019
DOI: https://doi.org/10.4143/crt.2019.122
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Diabetes mellitus (DM) is associated with elevated cancer risk and poor survival outcome in malignancies. The objective of this study was to evaluate the prognostic value of preexisting DM in chronic lymphocytic leukemia (CLL).
Materials and Methods
Six hundred and thirty-three subjects with newly-diagnosed CLL between 2007 and 2016 were recruited. Propensity score-matched method was performed to balance baseline characteristics and eliminate possible bias. Univariate and multivariate Cox regression analyses screened the independent risk indicators for time-to-first-treatment (TTFT) and cancer-specific survival (CSS) of CLL. Receiver operator characteristic curves and the corresponding areas under the curve assessed the predictive accuracy of CLL–International Prognostic Index (IPI) together with DM.
Results
The results showed that 111 patients had pre-existing DM. In the propensity-matched cohort, DM was correlated with inferior TTFT and CSS in CLL patients, and it was an independent prognostic factor for both CSS and TTFT. Pre-diabetics also shared undesirable prognostic outcome compared with patients with no diabetic tendency, and a positive association between longer diabetic duration and poorer prognosis of CLL was identified. DM as one additional point to CLL-IPI had larger area under the curve compared with CLL-IPI alone in CSS prediction and could improve the prognostic capacity of CLL-IPI.
Conclusion
Pre-existing DM was found to be a valuable prognostic predictor and could help predict life expectancy and build refined prognostication models for CLL.

Citations

Citations to this article as recorded by  
  • Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia
    Pouya Goleij, Mohammad Amin Khazeei Tabari, Ahmed Rabie Dahab Ahmed, Leena Mohamed Elamin Mohamed, Ghaida Ahmed Hamed Saleh, Malak Tarig Mohamed Abdu Hassan, Alaa Galal Mohammed Moahmmednoor, Haroon Khan
    Current Treatment Options in Oncology.2024;[Epub]     CrossRef
  • Causal associations between site-specific cancer and diabetes risk: A two-sample Mendelian randomization study
    Rong Xu, Tingjin Zheng, Chaoqun Ouyang, Xiaoming Ding, Chenjin Ge
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Association between diabetes and acute lymphocytic leukemia, acute myeloid leukemia, non-Hopkin lymphoma, and multiple myeloma
    Ji Zhong Zhao, Yu Cheng Lu, Yan Min Wang, Bo Lian Xiao, Hong Yan Li, Shao Chin Lee, Li Juan Wang
    International Journal of Diabetes in Developing Countries.2022; 42(4): 694.     CrossRef
  • Increased serum level of alpha-2 macroglobulin and its production by B-lymphocytes in chronic lymphocytic leukemia
    Regina Michelis, Lama Milhem, Evleen Galouk, Galia Stemer, Ariel Aviv, Tamar Tadmor, Mona Shehadeh, Lev Shvidel, Masad Barhoum, Andrei Braester
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • 8,238 View
  • 177 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma
Jin-Hua Liang, Yun-Ping Zhang, Jun Xia, Chong-Yang Ding, Wei Wu, Li Wang, Lei Cao, Hua-Yuan Zhu, Lei Fan, Tian-Nv Li, Jian-Yong Li, Wei Xu
Cancer Res Treat. 2019;51(4):1479-1487.   Published online March 12, 2019
DOI: https://doi.org/10.4143/crt.2018.649
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the prognostic significance of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) in patients with follicular lymphoma (FL) at baseline and mid-treatment with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) scans.
Methods
The study analyzed data from 48 patients with FL who were treated in Jiangsu Province Hospital and reviewed their baseline PET-CT scans. TMTV and TLG were computed by using the absolute value of 2.0, 2.5, and 3.0 thresholding method, respectively.
Results
Median age was 53 years, 75.0% of patients had stage III to IV disease, 43.8% had a Follicular Lymphoma International Prognostic Index 1 (FLIPI1) score of 3 to 5 and 20.8% had a FLIPI2 score of 3 to 5. Receiver operating characteristic (ROC) curve analysis showed the optimal cut-off values for TMTV3.0 and TLG3.0 were 476.4 (sensitivity, 85.7%; specificity, 78.0%; area under the curve [AUC], 0.760; p=0.003) and 2,676.9 (sensitivity, 71.4%; specificity, 78.0%; AUC, 0.760; p=0.003). On multivariable analysis, TMTV3.0 and TLG3.0 were independent predictors of both progression-free survival (PFS) (hazard ratio [HR], 5.406; 95% confidence interval [CI], 1.326 to 22.040; p=0.019 and HR, 6.502; 95% CI, 1.079 to 39.182; p=0.042) and overall survival (OS) (HR, 4.111; 95% CI, 1.125 to 15.027; p=0.033 and HR, 5.885; 95% CI, 1.014 to 34.148; p=0.049). ROC curve analysis showed the optimal cut-off values for ΔTMTV3.0 and ΔTLG3.0 were 66.3% (sensitivity, 85.7%; specificity, 63.4%; AUC, 0.774; p < 0.001) and 64.5% (sensitivity, 85.7%; specificity, 65.9%; AUC, 0.777; p < 0.001).
Conclusion
Baseline TMTV and TLG are strong predictors of PFS and OS in FL. Furthermore, interim TMTV (ΔTMTV > 66.3%) and TLG (ΔTLG > 64.5%) reduction are valuable tools for early treatment response assessment in FL patients.

Citations

Citations to this article as recorded by  
  • Personalised therapy in follicular lymphoma – is the dial turning?
    Kim M. Linton, Lena Specht, Astrid Pavlovsky, Carrie A. Thompson, Eva Kimby, Daphne de Jong, Loretta J. Nastoupil, Anne‐Ségolène Cottereau, Carla Casulo, Clémentine Sarkozy, Jessica Okosun
    Hematological Oncology.2024;[Epub]     CrossRef
  • Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
    A.S. Cottereau, L. Rebaud, J. Trotman, P. Feugier, L.J. Nastoupil, E. Bachy, I.W. Flinn, C. Haioun, L. Ysebaert, N.L. Bartlett, H. Tilly, O. Casasnovas, R. Ricci, C. Portugues, I. Buvat, M. Meignan, F. Morschhauser
    Annals of Oncology.2024; 35(1): 130.     CrossRef
  • Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma
    S. Draye-Carbonnier, V. Camus, S. Becker, D. Tonnelet, E. Lévêque, A. Zduniak, F. Jardin, H. Tilly, P. Vera, P. Decazes
    Scientific Reports.2024;[Epub]     CrossRef
  • Baseline 18F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma
    Qiao Yang, Hongzhe Zhang, Yan Zhang, Wei Zhang, Daobin Zhou, Yaping Luo
    European Journal of Radiology.2024; 178: 111632.     CrossRef
  • The value of semiquantitative PET features and end‐of‐therapy PET in grade 3B follicular lymphoma
    Allison Barraclough, Sze Ting Lee, Diego Villa, Greg Hapgood, Don Wilson, Geoffrey Chong, Eliza A. Hawkes
    British Journal of Haematology.2024;[Epub]     CrossRef
  • Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study
    Isabel Ródenas‐Quiñonero, Tzu Chen‐Liang, Taida Martín‐Santos, Antonio Salar, Marta Fernández‐González, Carolina Celades, José‐Tomás Navarro, Ana Belén Martínez‐Garcia, Rafael Andreu, Aitana Balaguer, Alejandro Martin García‐Sancho, Mónica Baile, Javier L
    Cancer Medicine.2023; 12(6): 6536.     CrossRef
  • Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL)
    Yiting Xie, Yue Teng, Chong Jiang, Chongyang Ding, Zhengyang Zhou
    Japanese Journal of Radiology.2023; 41(7): 777.     CrossRef
  • Prognostic value of interim 18F-FDG PET/CT in adult follicular lymphoma treated with R-CHOP
    Na Sun, Wenli Qiao, Yan Xing, Taisong Wang, Jinhua Zhao
    Annals of Hematology.2023; 102(4): 795.     CrossRef
  • Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
    Wojciech Cytawa, Robin Hendel, Bartłomiej Tomasik, Franz-Xaver Weinzierl, Thorsten Bley, Jacek Jassem, Andreas Schirbel, Andreas K. Buck, Ralph A. Bundschuh, Philipp E. Hartrampf, Rudolf A. Werner, Constantin Lapa
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(12): 3765.     CrossRef
  • Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy
    Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A. Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging.2022; 49(5): 1584.     CrossRef
  • Prognostic significance of clinical characteristics and 18Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma
    Yizhen Liu, Jinjin Jiang, Lianfang Liu, Zezhou Wang, Baohua Yu, Zuguang Xia, Qunling Zhang, Dongmei Ji, Xiaojian Liu, Fangfang Lv, Xiaonan Hong, Shaoli Song, Junning Cao
    Journal of International Medical Research.2022;[Epub]     CrossRef
  • Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
    Tarec Christoffer El‐Galaly, Diego Villa, Chan Yoon Cheah, Lars C. Gormsen
    British Journal of Haematology.2022; 197(2): 139.     CrossRef
  • Prediction of prognosis and pathologic grade in follicular lymphoma using 18F-FDG PET/CT
    Hongyan Li, Min Wang, Yajing Zhang, Fan Hu, Kun Wang, Chenyang Wang, Zairong Gao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Time to omit interim CT imaging during frontline chemoimmunotherapy for patients with follicular lymphoma?
    Ross Thomas Salvaris, Chan Yoon Cheah
    Leukemia & Lymphoma.2022; 63(14): 3271.     CrossRef
  • Prognostic Values of Baseline 18F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma
    Yeye Zhou, Xiaoyi Zhang, Haifeng Qin, Zixuan Zhao, Jihui Li, Bin Zhang, Shibiao Sang, Yiwei Wu, Shengming Deng
    BioMed Research International.2020; 2020: 1.     CrossRef
  • The Incremental Prognostic Value of Baseline 18F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma
    Hui Wang, Wenjing Yu, Tao Wu, Yangyang Xue, Dan Zhang, Huiqin Xu
    BioMed Research International.2020; 2020: 1.     CrossRef
  • 9,288 View
  • 210 Download
  • 18 Web of Science
  • 16 Crossref
Close layer
Albumin-to-Fibrinogen Ratio as an Independent Prognostic Parameter in Untreated Chronic Lymphocytic Leukemia: A Retrospective Study of 191 Cases
Yi-Xin Zou, Jia Qiao, Hua-Yuan Zhu, Rui-Nan Lu, Yi Xia, Lei Cao, Wei Wu, Hui Jin, Wen-Jie Liu, Jin-Hua Liang, Jia-Zhu Wu, Li Wang, Lei Fan, Wei Xu, Jian-Yong Li
Cancer Res Treat. 2019;51(2):664-671.   Published online August 1, 2018
DOI: https://doi.org/10.4143/crt.2018.358
AbstractAbstract PDFPubReaderePub
Purpose
Chronic lymphocytic leukemia (CLL) is one of the most frequent type of B-cell chronic lymphoproliferative disorders and chronic inflammation takes part in the development of CLL. However, there has been no valid immune biomarker to predict the prognosis of untreated CLL patients.
Materials and Methods
In this retrospective study, we analyzed the clinical correlations and prognostic value of albumin-to-fibrinogen ratio (AFR) detected at diagnosis in 191 CLL patients.
Results
The cut-off value of AFR was 9.7 calculated by X-tile. Patients who were more than 65 years old were often accompanied by low level of AFR (p < 0.001). Survival analysis showed that patients with low level of AFR had shorter overall survival (OS) than patients with high level of AFR (p < 0.001). Multivariate analysis illustrated that AFR had a negative impact on OS (p=0.003) and was independent of parameters involved in CLL international prognostic index and other prognostic markers such as CD38 and ZAP-70.
Conclusion
These data provide a comprehensive view of AFR and shows that AFR at diagnosis is an adverse prognostic factor in untreated CLL patients.

Citations

Citations to this article as recorded by  
  • Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome
    Suyan Duan, Si Chen, Chen Chen, Fang Lu, Ying Pan, Yifei Lu, Qing Li, Simeng Liu, Bo Zhang, Huijuan Mao, Changying Xing, Yanggang Yuan
    Renal Failure.2024;[Epub]     CrossRef
  • The diagnostic value of neutrophil to lymphocyte ratio, albumin to fibrinogen ratio, and lymphocyte to monocyte ratio in Parkinson’s disease: a retrospective study
    Yi-Ming Li, Xiao-Hu Xu, Li-Na Ren, Xiao-Fan Xu, Yi-Long Dai, Rui-Rui Yang, Cheng-Qiang Jin
    Frontiers in Neurology.2024;[Epub]     CrossRef
  • Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review
    D Abdelhafiz, T Baker, DA Glascow, Ah Abdelhafiz
    Postgraduate Medicine.2023; 135(3): 214.     CrossRef
  • Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma
    Di Wang, Bing Pan, Jin-Can Huang, Qing Chen, Song-Ping Cui, Ren Lang, Shao-Cheng Lyu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Albumin-to-fibrinogen ratio is an independent prognostic parameter in de novo non-M3 acute myeloid leukemia
    Yaqun Ding, Xiangyu Qi, Yang Li, Yanni Sun, Jia Wan, Chengxin Luo, Yarui Huang, Qingrong Li, Guixian Wu, Xiaoqing Zhu, Shuangnian Xu
    Clinical and Experimental Medicine.2023; 23(8): 4597.     CrossRef
  • The combination of preoperative fibrinogen-to-albumin ratio and postoperative TNM stage (FAR-TNM) predicts the survival in gastric cancer patients after gastrectomy
    Xunlei Zhang, Xinyue Qiu, Haibing Yin, Wenjing Zhao, Li Song, Xingsong Zhang, Lei Yang, Min Tao
    Biomarkers.2023; 28(8): 714.     CrossRef
  • Prognostic Significance of the Albumin to Fibrinogen Ratio in Peritoneal Dialysis Patients
    Wenkai Xia, Meisi Kuang, Chenyu Li, Xiajuan Yao, Yan Chen, Jie Lin, Hong Hu
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia
    Zheng Tian, Ming Liu, Xiaosheng Fang, Xiangxiang Zhou, Peipei Li, Ying Li, Lingyan Zhang, Fang Liu, Ya Zhang, Xin Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer
    Arina Onoprienko, Gerda Hofstetter, Tim Dorittke, Christine Bekos, Christoph Grimm, Mariella Polterauer, Thomas Bartl, Stephan Polterauer
    Journal of Personalized Medicine.2022; 12(11): 1882.     CrossRef
  • Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer
    Lin Fang, Fei-Hu Yan, Chao Liu, Jing Chen, Dan Wang, Chun-Hui Zhang, Chang-Jie Lou, Jie Lian, Yang Yao, Bo-Jun Wang, Rui-Yang Li, Shu-Ling Han, Yi-Bing Bai, Jia-Ni Yang, Zhi-Wei Li, Yan-Qiao Zhang
    Cancer Research and Treatment.2021; 53(1): 131.     CrossRef
  • A Novel Biomarker to Screen for Malnutrition: Albumin/Fibrinogen Ratio Predicts Septic Failure and Acute Infection in Patients Who Underwent Revision Total Joint Arthroplasty
    Zulipikaer Maimaiti, Chi Xu, Jun Fu, William Tianyu Li, Wei Chai, Yonggang Zhou, Jiying Chen
    The Journal of Arthroplasty.2021; 36(9): 3282.     CrossRef
  • The Albumin-to-Fibrinogen Ratio Independently Predicts Acute Kidney Injury in Infants With Ventricular Septal Defect Undergoing Cardiac Surgery With Cardiopulmonary Bypass
    Fan Cao, Xinxin Chen, Guodong Huang, Wenhua Liu, Na Zhou, Huili Yuan, Minghui Zou
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Is Serum C- Reactive Protein to Albumin Ratio Be A New Biomarker for Assessing Disease Activity and Quality of Life in Rheumatoid Arthritis?
    Elif BALEVİ BATUR, Funda LEVENDOĞLU
    OSMANGAZİ JOURNAL OF MEDICINE.2021;[Epub]     CrossRef
  • Correlation between albumin to fibrinogen ratio, C-reactive protein to albumin ratio and Th17 cells in patients with rheumatoid arthritis
    Yujue He, Jifeng Tang, Bodeng Wu, Bin Yang, Qishui Ou, Jinpiao Lin
    Clinica Chimica Acta.2020; 500: 149.     CrossRef
  • Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis
    Da-wei Sun, Lin An, Guo-yue Lv
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef
  • The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis
    Ziyan Zhang, Rui Zhang, Jiaqian Qi, Wenjing Miao, Kun Fang, Changgeng Ruan, Depei Wu, Yue Han
    Leukemia & Lymphoma.2020; 61(11): 2682.     CrossRef

  • Nomogram to Predict Preoperative Occult Peritoneal Metastasis of Gastrointestinal Stromal Tumors (GIST) Based on Imaging and Inflammatory Indexes


    Shao-Jun Xu, Guo-Sheng Lin, Hong-Jian Ling, Ren-Jie Guo, Jie Chen, Yi-Ming Liao, Tao Lin, Yong-Jian Zhou
    Cancer Management and Research.2020; Volume 12: 11713.     CrossRef
  • Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer
    Wen Yu, Zhongxue Ye, Xi Fang, Xingzhi Jiang, Yafen Jiang
    Journal of Ovarian Research.2019;[Epub]     CrossRef
  • 9,046 View
  • 242 Download
  • 20 Web of Science
  • 18 Crossref
Close layer
Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
Ya-Ping Zhang, Run Zhang, Hua-Yuan Zhu, Li Wang, Yu-Jie Wu, Jin-Hua Liang, Wen-Yu Shi, Hong Liu, Wei Xu, Jian-Yong Li
Cancer Res Treat. 2019;51(1):368-377.   Published online May 14, 2018
DOI: https://doi.org/10.4143/crt.2018.010
AbstractAbstract PDFPubReaderePub
Purpose
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non-Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL.
Materials and Methods
We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS).
Results
Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30×109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low ACD4C cohort. There were significant differences in both OS and PFS between the two cohorts. Moreover, multivariate Cox analysis identified ACD4Cs as an independent predictor for OS and PFS.
Conclusion
Low ACD4Cs were associated with poorer survival and could act as a negative predictor for ENKTL patients treated with asparaginase-based regimens.

Citations

Citations to this article as recorded by  
  • Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma
    Xin Zhang, Xinli Liu, Renhua Xiong, Han-Xiang An
    Aging.2022;[Epub]     CrossRef
  • An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
    Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma
    Jason Yongsheng Chan, Jing Quan Lim, Choon Kiat Ong
    Life.2021; 11(8): 838.     CrossRef
  • The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma
    Shengnan Zhang, Mengjuan Li, Fangfang Yuan, Lin Chen, Ruihua Mi, Xudong Wei, Yongping Song, Qingsong Yin
    Cancer Cell International.2019;[Epub]     CrossRef
  • It’s all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma
    Jonathan Moreira, Leonidas C. Platanias, Kehinde U. A. Adekola
    Leukemia & Lymphoma.2019; 60(10): 2345.     CrossRef
  • The combined prognostic value of pretreatment neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in stage IE/IIE extranodal natural killer/T-cell lymphoma
    Xiaoying Quan
    Oncology and Translational Medicine.2019; : 137.     CrossRef
  • 8,158 View
  • 217 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH
Jin-Hua Liang, Luo Lu, Hua-Yuan Zhu, Wang Li, Lei Fan, Jian-Yong Li, Wei Xu
Cancer Res Treat. 2019;51(1):150-157.   Published online April 2, 2018
DOI: https://doi.org/10.4143/crt.2017.476
AbstractAbstract PDFPubReaderePub
Purpose
Determine the frequency and prognostic value of circulating Epstein-Barr virus (EBV) DNA copy number in angioimmunoblastic T-cell lymphoma (AITL) patients who were treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) regimens.
Materials and Methods
Sixty newly-diagnosed AITL patients were retrospectively enrolled in the present study. All patients were treated with DA-EPOCH regimen.
Results
Twenty-two subjects (36.7%) had a EBV DNA-positive test at diagnosis. EBV DNA‒positive patients were associated with lower lymphocyte-monocyte ratio (p=0.024). Median follow-up was 40 months (range, 14 to 100 months). The overall response rate for all the 60 AITL patents were 71.7% (95% confidence interval [CI], 58.6 to 82.5) with 3-year progressive-free survival (PFS) rate of 30.9%±6.1% and overall survival (OS) rate of 60.1%±6.6%. Not only did PFS estimation differ between the EBV DNA‒positive and EBV DNA‒negative group (hazard ratio [HR], 2.24; 95% CI, 1.15 to 4.35; p=0.006), but also worse OS was observed in the pretreatment EBV DNA‒positive group than in the EBV DNA‒negative group (HR, 2.74; 95% CI, 1.22 to 6.19; p=0.006). EBV DNA test positivity was independent prognostic marker for both PFS (HR, 2.17; 95% CI, 1.17 to 4.00; p=0.014) and OS (HR, 3.24; 95% CI, 1.48 to 7.11; p=0.004) after adjusting International Prognostic Index and prognostic index for AITL score. Reduction in EBV copies was significantly associated with therapy-response.
Conclusion
Circulating EBV DNA level was an important prognostic and monitoring marker for AITL patients who treated with DA-EPOCH regimens which cannot improve outcomes for AITL patients.

Citations

Citations to this article as recorded by  
  • Impact of the peripheral blood inflammatory indices and modified nomogram-revised risk index on survival of Extranodal Nasal-Type Natural Killer/T-Cell lymphoma
    Qing Hou, He Li, Yu Liang, Ningning Yao, Xin Cao, Jianting Liu, Bochen Sun, Peixin Feng, Wenjuan Zhang, Jianzhong Cao
    Cancer Biomarkers.2024; 39(1): 27.     CrossRef
  • Cutaneous peri‐ocular involvement in angioimmunoblastic T‐cell lymphoma
    M. Mathieu, M. de Vicq de Cumptich, A. Kul, B. Richert
    Journal of the European Academy of Dermatology and Venereology.2024;[Epub]     CrossRef
  • Real-world study and prognostic analysis of angioimmunoblastic T-cell lymphoma
    Suxiao Li, Xiaoyan Feng, Yunfei Song, Mengke Fan, Qingjiang Chen, Mingzhi Zhang, Xiaolong Wu, Meng Dong, Jieming Zhang, Lijuan Han, Xudong Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
    Jing Zhang, Shuchao Qin, Ze Jin, Qingqing Chen, Lingxiao Xing, Tonglu Qiu, Yi Xia, Jinhua Liang, Huayuan Zhu, Li Wang, Lei Fan, Wei Xu, Jianyong Li, Yi Miao
    Journal of Clinical Immunology.2023; 43(6): 1302.     CrossRef
  • Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV+ DLBCL-NOS: a Chinese cohort study
    Tong-Yao Xing, Zi-Wen Duan, Wei-Ting Wang, Kai-Xin Du, Hao-Rui Shen, Hua Yin, Jia-Zhu Wu, Yue Li, Li Wang, Jian-Yong Li, Jin-Hua Liang, Wei Xu
    Annals of Hematology.2023; 102(9): 2471.     CrossRef
  • Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma
    Tong-Yoon Kim, Gi-June Min, Young-Woo Jeon, Sung-Soo Park, Silvia Park, Seung-Hawn Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Seok-Goo Cho
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Comprehensive analysis of the differential cellular and EBV miRNA expression profiles in mature T and NK cell lymphomas
    Zheng Cao, Linshu Zeng, Lin Feng, Xiaoli Feng
    Pathology - Research and Practice.2022; 233: 153846.     CrossRef
  • Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma
    Jia-Qi Qin, Hua Yin, Jia-Zhu Wu, Rui-Ze Chen, Yi Xia, Li Wang, Hua-Yuan Zhu, Lei Fan, Jian-Yong Li, Jin-Hua Liang, Wei Xu
    Leukemia Research.2021; 107: 106607.     CrossRef
  • Diagnostic Considerations in the Evaluation of Large B-Cells on Lymph Node Cytology Specimens
    Daniel F. Boyer, Sarah Choi, Winston Lee, Shannon Carty, Bryan L. Betz, Noah Brown, Madelyn Lew
    Acta Cytologica.2021; 65(1): 105.     CrossRef
  • Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?
    Davide Facchinelli, Alice Parisi, Mauro Krampera, Dino Veneri
    Tumori Journal.2020; 106(5): 424.     CrossRef
  • Development of a Novel Clinical Prognostic Model for Patients With Angioimmunoblastic T-Cell Lymphoma
    Chen Huang, Huichao Zhang, Yuhuan Gao, Lanping Diao, Lihong Liu
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr virus positivity and its effects on clinicopathologic features
    Woo Jin Lee, Kwang Hee Won, Jae Won Choi, Chong Hyun Won, Sung Eun Chang, Jee Ho Choi, Mi Woo Lee
    Journal of the American Academy of Dermatology.2019; 81(4): 989.     CrossRef
  • The predictive value of dynamic monitoring of peripheral blood lymphocyte to monocyte ratio in patients with extranodal NK/T cell lymphoma
    Shengnan Zhang, Mengjuan Li, Fangfang Yuan, Lin Chen, Ruihua Mi, Xudong Wei, Yongping Song, Qingsong Yin
    Cancer Cell International.2019;[Epub]     CrossRef
  • 11,506 View
  • 245 Download
  • 16 Web of Science
  • 13 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP